Jonhson&Jonhson hurries up Genmab’s myeloma treatment

15/06/2015 - 2 minutes

Genmab and its partner Jonhson&Jonhson, through its subsidiary Janssen Biotech, are trying to speed up daratumumab. The companies initiated a rolling submission for the candidate that targets multiple myeloma.

The German-American partnership is trying to accelerate the arrival of daratumumab to the market, only just after the presentation of optimistic results of MOR202’s phase I/IIa. Morphosys’ candidate for the same indication as J&J’s, was doubted after Celgene abandoned the project. MOR202 cleared up all negative impressions so far on it, but the drug is still in an earlier stage than daratumumab, whose remarkable phase II was presented in ASCO.

Both candidates target the same transmembrane enzyme, CD38, which is present on the surface of multiple myeloma cells as well as in other malignant diseases. The antibodies induce rapid tumor cell death through diverse mechanisms of action.

J&J might feel that Morphosys is on its heels and, after all, they are competing for an approximate €3.5Bn market,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member